Cite
HARVARD Citation
Park, Y. et al. (2019). Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet oncology. 20 (12), pp. 1750-1759. [Online].